Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

142
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
142
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

1.5K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
1.5K
Dysrhythmias III: Characteristics of Dysrhythmias01:29

Dysrhythmias III: Characteristics of Dysrhythmias

148
Dysrhythmias, also known as arrhythmias, are irregular heart rhythms that result from abnormal electrical activity in the heart, affecting its ability to circulate blood efficiently. Tachyarrhythmias, a subset of dysrhythmias, are characterized by abnormally fast heart rates exceeding 100 beats per minute. Here are some types of tachyarrhythmias with their distinct ECG features:Sinus Tachycardia:Sinus tachycardia presents a regular heart rhythm with an increased rate of 101-180 beats per...
148
Pulse rhythm01:30

Pulse rhythm

975
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
975
Dysrhythmias II: Classification of Tachyarrhythmias01:28

Dysrhythmias II: Classification of Tachyarrhythmias

153
Tachyarrhythmias are a type of dysrhythmia where the heart rate exceeds 100 beats per minute. Here are some common types of tachyarrhythmias:Sinus TachycardiaSinus tachycardia originates from increased impulses from the sinus node, leading to an elevated heart rate. It is often triggered by stress, fever, or exercise.Patients may experience palpitations, a sensation of a racing heart, dizziness, and chest discomfort.Causes and Risk Factors: Common causes include physical exertion, emotional...
153
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

195
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
195

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expanding Addressable KRAS Mutations through the Structure- and Property-Based Design of Dual-State (GDP/GTP), Reversible Pan-KRAS Inhibitors.

Journal of medicinal chemistry·2026
Same author

Identifying the Presence and Characteristics of Mid-Myocardial and Epicardial Fibrosis From Intracardiac Electrograms in Patients Undergoing Ventricular Arrhythmia Ablation Using a Transformer-Based Self-Supervised Classifier.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Cardiac remodelling and dysfunction in cancer patients receiving cardiotoxic therapies: proteomic and metabolomic profiling.

European heart journal·2026
Same author

Antithetic Sampling Enhanced Probabilistic Diffusion for Denoising Cardiac Time Series.

IEEE journal of biomedical and health informatics·2026
Same author

Deep Learning-Based Prediction of Heart Failure Readmission Using Longitudinal Cardiac Device Data.

Journal of cardiovascular electrophysiology·2026
Same author

Polyethylene and Polyvinyl Chloride Nanoplastics Accelerate Atherosclerosis Through Distinct Smooth Muscle Cell Phenotypic Transitions.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Oct 6, 2025

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K

Arrhythmia Patterns in Patients on Ibrutinib.

Muhammad Fazal1, Ridhima Kapoor2, Paul Cheng1

  • 1Department of Medicine, Division of Cardiovascular Medicine, Stanford University, Palo Alto, CA, United States.

Frontiers in Cardiovascular Medicine
|January 20, 2022
PubMed
Summary

Ibrutinib treatment for blood cancers is linked to a high rate of atrial and ventricular arrhythmias, often requiring treatment changes. This study highlights the need for better monitoring and management of these cardiac events in patients on ibrutinib.

Keywords:
ambulatory event monitoratrial fibrillationcardio-oncologyibrutinibtyrosine kinase inhibitorventricular arrhythmia

More Related Videos

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.5K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.9K

Related Experiment Videos

Last Updated: Oct 6, 2025

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.0K
Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

15.5K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.9K

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Ibrutinib, a Bruton's tyrosine kinase inhibitor (TKI), is a key treatment for hematologic malignancies.
  • Previous studies suggest an association between ibrutinib and atrial fibrillation (AF), but comprehensive data on other tachyarrhythmias are limited.
  • Understanding the full spectrum of cardiac arrhythmias associated with ibrutinib is crucial for patient management.

Purpose of the Study:

  • To investigate the prevalence and burden of atrial and ventricular arrhythmias (VAs) in patients receiving ibrutinib therapy.
  • To assess the impact of these arrhythmias on treatment continuation and management.

Main Methods:

  • Retrospective analysis of electronic medical records from a single center.
  • Inclusion of consecutive patients who underwent ambulatory cardiac event monitoring while on ibrutinib.
  • Chart review to identify and analyze documented arrhythmias.

Main Results:

  • Seventy-two patients were analyzed; 18% had pre-existing AF.
  • Common arrhythmias included non-AF supraventricular tachycardia (44.4%), AF (44%), and non-sustained ventricular tachycardia (43%).
  • Significant burdens of premature atrial contractions (>1% in 18%) and premature ventricular contractions (>1% in 22.2%) were observed.
  • Ibrutinib was interrupted in 25% of patients due to arrhythmias; 8.3% required antiarrhythmic drug initiation.

Conclusions:

  • Ambulatory cardiac monitoring reveals a high prevalence of atrial and ventricular arrhythmias in patients treated with ibrutinib.
  • Arrhythmias frequently lead to treatment interruptions and necessitate further management strategies.
  • Further research is needed to optimize the diagnosis, monitoring, and management of ibrutinib-associated arrhythmias.